Actively Recruiting
Phase 1 Study of Oral GLB-001 to Evaluate Safety and Effectiveness in Adults with Relapsed or Refractory Acute Myeloid Leukemia or Higher-risk Myelodysplastic Syndromes
Led by GluBio Therapeutics Inc. · Updated on 2026-04-13
48
Participants Needed
8
Research Sites
14 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating GLB-001, an oral drug, in a first-in-human Phase 1 clinical trial for adults with relapsed or refractory acute myeloid leukemia RR AML or relapsed or refractory higher-risk myelodysplastic syndromes RR HR-MDS. The study aims to assess the safety, tolerability, how the drug moves and acts in the body, and initial effectiveness. The trial includes a dose escalation phase to find the highest safe dose and a dose expansion phase to confirm tolerability and explore clinical activity. The trial uses a standard dose-escalation design in Phase 1a to evaluate several dose levels of GLB-001, adjusting dose amounts or frequency based on safety and pharmacokinetic data. After determining the maximum tolerated or administered dose, Phase 1b will enroll participants at one or two selected dose levels to confirm tolerability and assess whether the drug shows enough activity to continue development. GLB-001 is given orally based on the assigned treatment schedule. Participants will be closely monitored for dose-limiting toxicities during the first 28 days, as well as adverse events over up to two years. Researchers will measure drug levels in the body, response rates such as remission, progression-free survival, and overall survival. Safety reviews will guide dose selection for future studies. The total study duration includes long-term follow-up to track outcomes and safety for up to two years after treatment begins.
CONDITIONS
Brief Title
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Research Team
K
Kimberly Glen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here